Inspiring Business “TECNALIA TRANSFORMS KNOWLEDGE INTO GDP TO IMPROVE THE LIVES OF INDIVIDUALS WHILE CREATING BUSINESS OPPORTUNITIES FOR COMPANIES”.
TECNALIA Research & Innovation is the first private applied Research Centre in Spain and one of Europe’s leaders. A blend of technology, drive, effectiveness, boldness and imagination. The 1,500 researchers of TECNALIA are organised into 16 sectorfocused Business Units that are 100% interlinked and grouped into 5 Divisions: Health, Industry and Transport, Sustainable development, ICT-European Software Institute, and Innovation and Society. This way of working is the best example of its innovative spirit applied to an operating model where cooperation really works, thanks to the transversal nature of our equipment, projects and clients, all collaborating to contribute their experience, commitment and knowledge. TECNALIA, Inspiring Business.
TECNALIA OPHTHALMOLOGY
We are a multi-disciplinary team made up by 25 researchers specialised in the fields of health-oriented biotechnology, biomaterials and pharmaceuticals. We develop innovative products for companies operating in the fields of medical devices and advanced therapies for ophthalmology field.
PRODUCTS
TECHNOLOGIES
SERVICES
Bioactive implants
Hydrogels
I+D projects
Corneal explants
Decellularization of tissues
Technological services
Controlled delivery systems
Micro and nanoparticles
Consultancy
Advanced therapies for tissue
Cell encapsulated systems
regeneration
Biofuntionalization of biomaterials
Biocompatibility assays / In vitro
Extraction and culture of primary cells
and in vivo behaviour
In vitro and in vivo characterization CE marking- biocompatibility
“WE HAVE DEVELOPED A BIOACTIVE AND MODULAR KERATOPROSTHESIS FOR CORNEAL DISORDER APPLICATIONS”.
It combines cells and a substance-releasing system that provides therapeutic and regenerative properties to the implant for its subsequent use in patients with corneal blindness, refractive errors, keratoconus and corneal ectasia. This implant is a qualitative leap compared to existing therapies, since it is a viable alternative to transplants. To avoid endless waiting lists and common rejection risks.
www.tecnalia.com